secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001628280-24-020841
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q1 revenue $137.7M (+467% YoY), net income of $61.0M; FDA label expansion expands market
--------------------------------------------------------------------------------

- Total revenue $137.7M vs $24.3M YoY; U.S. net product revenue $24.8M (+46% YoY).
- Net income of $61.0M ($0.36 basic EPS) vs net loss of $61.7M in Q1 2023.
- FDA approved label expansions for NEXLETOL/NEXLIZET to add CV risk reduction and use without statin.
- Cash balance $226.6M at quarter end, up from $82.2M at Dec 31, 2023.
- FY 2024 operating expense guidance maintained at $225M-$245M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024020841/0001628280-24-020841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024020841/espr-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-020841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer